FCF Healthcare & Life Sciences
Venture Capital Monitor
-
Europe

The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Healthcare & Life Sciences industry.

FCF Healthcare & Life Sciences Venture Capital Monitor - Europe

As of the end of December 2024 we identified the following current VC trends in Europe:

    • In 2024 total Healthcare & Life Sciences VC-funding volume reached EUR 9,090m. This represents an increase of 16.2% vs. 2023 funding volume (EUR 7,824m)
    • Biotech & Pharma received 60% of the total investment volume (EUR 5,497m) with oncology being the leading indication (46%)
    • In contrast to increased funding volume in 2024 the total number of VC-deals declined by 8.5% vs. prior year (890 VC deals in 2024 vs. 973 VC deals in 2023)
    • Therefore, on average 2024 saw a smaller number of VC-deals but with larger ticket sizes (2024 average ticket size of EUR 10,2m vs. EUR 8.0m in 2023)
    • In 2024 General Atlantic (USA) was the most active investor (by deal volume), followed by Forbion (NL) and European Innovation Council Fund (BEL)
    • In the month of December 2024, Noema Pharma (SWI) secured the highest transaction volume with EUR 139m, followed by Ottimo Pharma (GBR) with EUR 133m and Citryll (NL) with EUR 85m
FCF Life Sciences Venture Capital Monitor - Europe
ETC.....

NEWS